Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | SPR | P35270 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.44 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | PRKACG | P22612 | 1/20 | 0.44 |
| ▸ | PRKACB | P22694 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8267253 | 0.84 | RAB9A (0.71) | MAPTRAB9ASMN1; SMN2SPRPDE5A | |
| SCHEMBL29397961 | 0.83 | SPR (0.69) | MAPTRAB9ASMN1; SMN2SPRPDE5A | |
| SCHEMBL22287887 | 0.83 | SPR (0.69) | MAPTRAB9ASMN1; SMN2SPRPDE5A | |
| SCHEMBL259507 | 0.81 | RAB9A (0.59) | MAPTRAB9ASMN1; SMN2BRD4GAA | |
| SCHEMBL259607 | 0.80 | RAB9A (0.55) | MAPTRAB9ASMN1; SMN2SPRRXFP1 | |
| SCHEMBL22287932 | 0.79 | RAB9A (0.54) | MAPTRAB9ASMN1; SMN2SPRRXFP1 | |
| SCHEMBL12112025 | 0.77 | RNASEL (0.46) | MAPTRXFP1RNASELBRD4PIK3CA | |
| SCHEMBL20303285 | 0.77 | MAPT (1.00) | MAPTRAB9ASMN1; SMN2SPRRXFP1 | |
| SCHEMBL30004904 | 0.77 | MAPT (1.00) | MAPTRAB9ASMN1; SMN2SPRRXFP1 | |
| SCHEMBL873906 | 0.76 | TNKS (0.71) | MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035431-B1 | THIENO[3,2-D]PYRIMIDINES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE FOR THE TREATMENT OF CANCER DISEASES | HOFFMANN LA ROCHE (CH) | 2016-02-03 | — | — | EP | disclosed |
| EP-1812446-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-11-18 | — | — | EP | disclosed |
| EP-1812446-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-11-18 | — | — | EP | disclosed |
| CN-101479276-B | Pharmaceutical compounds | HOFFMANN LA ROCHE | 2012-11-14 | — | — | CN | disclosed |
| US-8153639-B2 | kinase inhibitor; immunotherapy; viricides; function or behavior associated with PI3 kinase such as cancer, immune, cardiovascular, nervous system, metabolism/endocrine and neurological diseases, viral infection, inflammation; 3-(4-Pyridin-4-yl-thieno[3,2-d]pyrimidin-2-yl)-phenol | F. HOFFMAN-LA ROCHE AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-8153639-B2 | kinase inhibitor; immunotherapy; viricides; function or behavior associated with PI3 kinase such as cancer, immune, cardiovascular, nervous system, metabolism/endocrine and neurological diseases, viral infection, inflammation; 3-(4-Pyridin-4-yl-thieno[3,2-d]pyrimidin-2-yl)-phenol | F. HOFFMAN-LA ROCHE AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-7872003-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-18 | — | — | US | disclosed |
| US-7872003-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-18 | — | — | US | disclosed |
| US-7872003-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-18 | — | — | US | disclosed |
| US-20090209559-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
| CN-101479276-A | Pharmaceutical compounds | HOFFMANN LA ROCHE (CH) | 2009-07-08 | — | — | CN | disclosed |
| EP-2035431-A1 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-18 | — | — | EP | disclosed |
| US-20080207609-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207609-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207609-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| WO-2007132171-A1 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132171-A1 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-11-22 | — | — | WO | disclosed |
| EP-1812446-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006046040-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006046040-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209559-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3CD | MAPT 2297/4885RAB9A 655/4885SMN1; SMN2 1650/4885 |
| US-20080207609-A1 | Pharmaceutical compounds | PIK3CA, JAK2, PIK3R1 | MAPT 2811/4885RAB9A 637/4885SMN1; SMN2 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.